Source: Annual Congress 2013 –COPD treatment and others
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Gashynova (Dnipropetrovsk, Ukraine). Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 3657

Member's Comments

No comment yet.

Related content which might interest you: Plasma surfactant protein D (SP-D) and smoking status in patients with COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 The relationship between systemic inflammation and vitamin D levels in COPD Source: Annual Congress 2013 –Factors associated with outcomes in COPD Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The effects of endogenous and exogenous vitamin D on the rate of mature elastin degradation in COPD patients Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 The relationship between surfactant protein D and respiratory functions in COPD Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Serum leptin, adponectin and its tissue expression in COPD patients with osteopenic syndrome Source: International Congress 2015 – COPD: notable points Year: 2015 LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Serum vitamin D3 level correlates with FEV1 in patients with advanced COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Plasma levels of TIPM-2 in patients with COPD Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Relationship between plasma amino acid levels and lung function decline in patients with COPD Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Serum sirtuin-1 is reduced in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory Source: Annual Congress 2013 –COPD treatment Year: 2013 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015